MTDH Monoclonal Antibody

Downregulates SLC1A2/EAAT2 promoter activity when expressed ectopically. Activates the nuclear factor kappa-B (NF-kappa-B) transcription factor. Promotes anchorage-independent growth of immortalized melanocytes and astrocytes which is a key component in tumor cell expansion. Promotes lung metastasis and also has an effect on bone and brain metastasis, possibly by enhancing the seeding of tumor cells to the target organ endothelium. Induces chemoresistance.,induction:By TNF-alpha (at protein level). By HIV-1 infection of primary fetal astrocytes.,miscellaneous:Knockdown significantly reduces the adhesion of cancer cells to lung microvascular endothelial cells and the reciprocal effect is observed following overexpression.,subcellular location:In epithelial cells, recruited to tight junctions (TJ) during the maturation of the TJ complexes. A nucleolar staining may be due to nuclear targeting of an isoform lacking the transmembrane domain (By similarity). TNF-alpha causes translocation from the cytoplasm to the nucleus.,subunit:Interacts with BCIPP, CREBBP/CBP and RELA/p65.,tissue specificity:Widely expressed with highest levels in muscle-dominating organs such as skeletal muscle, heart, tongue and small intestine and in endocrine glands such as thyroid and adrenal gland. Overexpressed in various cancers including breast, brain, prostate, melanoma and glioblastoma multiforme.

Introducing the MTDH Monoclonal Antibody, a cutting-edge biotechnological innovation designed to revolutionize the field of medical research and diagnostics. This meticulously crafted antibody is meticulously engineered to specifically target and bind to the Metadherin (MTDH) protein, enabling precise detection and analysis of this crucial biomarker.

The MTDH Monoclonal Antibody boasts exceptional specificity and sensitivity, ensuring accurate identification and quantification of MTDH protein expression levels in various biological samples. Its high affinity for MTDH guarantees reliable and reproducible results, facilitating comprehensive investigations into the role of MTDH in disease progression and therapeutic response.

With its advanced formulation, this antibody exhibits exceptional stability and longevity, allowing for prolonged storage and repeated usage without compromising its performance. Its compatibility with a wide range of experimental techniques, including Western blotting, immunohistochemistry, and flow cytometry, further enhances its versatility and applicability across diverse research settings.

Moreover, the MTDH Monoclonal Antibody is manufactured under stringent quality control measures, adhering to the highest industry standards. Each batch undergoes rigorous testing to ensure batch-to-batch consistency, guaranteeing reliable and reproducible outcomes. This commitment to quality assurance ensures that researchers can confidently rely on this antibody for their critical investigations.

In summary, the MTDH Monoclonal Antibody represents a breakthrough in the field of biomedical research, offering an invaluable tool for elucidating the intricate mechanisms underlying various diseases. Its exceptional specificity, sensitivity, and compatibility make it an indispensable asset for scientists and clinicians alike, propelling advancements in personalized medicine and targeted therapies. Embrace the future of scientific discovery with the MTDH Monoclonal Antibody.